Taysha Gene Therapies is a Dallas-based biotechnology company dedicated to eradicating monogenic central nervous system (CNS) diseases. With a proven gene therapy strategy and a pipeline focused on CNS monogenic diseases, Taysha aims to bridge the gap between innovation and potential cures, offering hope to patients with high unmet medical needs.
Committed to being an ally to the rare disease community, Taysha Gene Therapies brings together top talent in gene therapy to discover, develop, and commercialize novel gene therapies for both rare and large patient populations. Their lead program, targeting Rett syndrome, is part of an extensive AAV gene therapy pipeline that addresses the underlying biology of specific indications.
Generated from the website